Does mixed DNA inside a head-and-neck tumor predict death?
In 305 TCGA HNSCC patients, high intra-tumor MATH heterogeneity more than doubled the hazard of death (HR 2.2; 95% CI 1.4–3.3), even after HPV, TP53, grade, and N classification.
Source
Intra-tumor genetic heterogeneity and mortality in head and neck cancer: analysis of data from the Cancer Genome Atlas
Study at a glance
- Design
- Cohort — Retrospective TCGA analysis of bulk-tumor WES MATH vs overall survival in HNSCC (diagnoses 1992–2011).
- N
- N=305 · 305 HNSCC patients from 14 institutions; 131 deaths (median time to death 14 months); living median follow-up 22 months.
- Population
- TCGA head and neck squamous cell carcinoma cases with clinical and whole-exome data (October 2013 freeze).
- Outcome
- Overall survival associated with high vs low mutant-allele tumor heterogeneity (MATH).
Structured fields used in claim comparison tables when every cited study has a complete layer.
Inspect source passages
Does mixed DNA inside a head-and-neck tumor predict death?
These passages occur verbatim in the stored paper text. They support the points listed below; they do not verify every statement in the explanation.
305 HNSCC patients from 14 institutions were analyzed.
Clinical and WES data were obtained from The Cancer Genome Atlas in October 2013 for 305 patients with head and neck squamous cell carcinoma (HNSCC), from 14 institutions.
High vs low MATH HR for death was 2.2 (95% CI 1.4–3.3).
hazard ratio for high/low heterogeneity, 2.2; 95% CI 1.4 to 3.3
What they did
Calculated MATH from bulk-tumor whole-exome sequencing for 305 HNSCC cases from 14 institutions and related high vs low MATH to overall survival with Cox models, including multivariate adjustment for standard clinical/molecular factors.
What they found
High MATH HR was 2.2 (univariate ~2.18). The association was not explained by age, HPV, grade, TP53, or N class, improved prognostication, and still split oral-cavity and laryngeal outcomes after staging. Chemoradiotherapy patients showed a particularly large HR (5.2).
The limits
What it doesn't show
Retrospective multi-site TCGA data were not collected to study MATH; prospective, homogeneously treated series (especially HPV+ oropharynx) are still required before clinical use.
Key terms
- MATH
- Mutant-allele tumor heterogeneity: a WES-based summary of how spread-out mutant allele fractions are in bulk tumor DNA.
- HNSCC
- Head and neck squamous cell carcinoma; 305 TCGA cases here.
- Intra-tumor genetic heterogeneity
- Mixture of genetically distinct tumor cells; MATH is a bulk-DNA proxy.
- TCGA
- The Cancer Genome Atlas; source of the WES and clinical files (Oct 2013).
- HPV-positive HNSCC
- Usually better prognosis; MATH added information beyond HPV status, but HPV+ oropharynx still needs dedicated study.
Flashcards
0 of 10 answers reviewed
Research intelligence for this paper
See its role on concept claims, tensions it is part of, placement history, and related discoveries.
Quiz yourself
TCGA HNSCC n was:
Common questions
How many patients?
305 HNSCC cases from 14 institutions.
High vs low MATH survival HR?
About 2.2 (95% CI 1.4–3.3).
Was it just HPV or TP53 in disguise?
No—the MATH–mortality link persisted after those and other standard factors.
Ready for clinic?
Not yet—authors require prospective, site-specific, homogeneously treated studies.
More on Oncology outcomes